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Abstract 
Within the myriad articles about participants’ opinions of genomics research, the views 
of a distinct group – people with a rare disease (RD) – are unknown. It is important to 
understand if their opinions differ from the general public by dint of having a rare disease 
and vulnerabilities inherent in this. Here, we document RD patients’ attitudes to 
participation in genomics research, particularly around large-scale, international data and 
biosample sharing. This work is unique in exploring the views of people with a range of 
rare disorders from many different countries. 
The authors work within an international, multidisciplinary consortium, RD Connect, 
which has developed an integrated platform connecting databases, registries, biobanks 
and clinical bioinformatics for RD research. Focus groups were conducted with 52 RD 
patients from 16 countries. Using a scenario based approach, participants were 
encouraged to raise topics relevant to their own experiences, rather than these being 
determined by the researcher.  Issues include wide data sharing, consent for new uses of 
historic samples and for children. 
Focus group members are positively disposed towards research and towards allowing 
data and biosamples to be shared internationally. Expressions of trust and attitudes to risk 
are often affected by the nature of the RD which they have experience of, as well as 
regulatory and cultural practices in their home country. Participants are concerned about 
data security and misuse. There is an acute recognition of the vulnerability inherent in 
having a RD and the possibility that open knowledge of this could lead to discrimination. 
Keywords: rare disease, genomics, social, data sharing, international 
  
3 
 
Introduction 
Widespread use of next generation sequencing (NGS) is changing the landscape of rare 
disease research. As technologies become faster and cheaper the identification of disease-
modifying genes, the understanding of rare disease mechanisms and investigation into 
therapeutic approaches have all accelerated 1. Patients, data and samples for individual 
disorders are both scarce and diverse and the relative rarity of resources means 
collaboration and transnational working are key to research which aims to improve 
understanding of RD, advance care and develop therapies 2 3. 
 
Patient registries and biobanks are recognised as valuable resources for researching the c. 
6,000 RDs, but they have traditionally been organised around single diseases and often 
replicated in different regions. Unless the required data can be found in one of the few 
collaborative ventures (EuroBioBank, TREAT-NMD), a researcher either has access to 
only a small set of local data and samples or undertakes the time consuming task of 
requesting samples and/or data from individual repositories 4-6 7. 
 
The founding of the International Rare Disease Research Consortium (IRDiRC) in 2011 
and the distribution of €144m of funding for RD research, via the European’s 
Commission’s 7th Framework Programme (FP7), have provided significant impetus for 
rare disease research and with it, ‘a strong rallying call for openness’ 8. Three of the 
projects funded by FP7 – RD-Connect, NeurOmics and EURenOmics – concentrate on 
omics approaches to RD and provide infrastructure to allow new and existing RD 
resources to be connected. This work is part of RD-Connect which is linking databases, 
registries, biobanks and clinical bioinformatics data into a single resource internationally. 
Practically this means collating details of available RD research data and biosamples into 
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a searchable online catalogue, ensuring data is interoperable and providing ethical, legal 
and logistical frameworks that will allow access via a global platform 9,10. 
 
Collation and distribution of personal genomics data and biosamples raises issues related 
to patient and public trust 11-13. Understanding what those issues are and how they affect 
patients’ and the public’s perceptions of an international database is intrinsic to the 
success of such a platform 14 15. To this end, this exploratory study documents the hopes, 
expectations and concerns of RD patients, as identified by participants themselves, in the 
changing landscape of NGS and international data sharing. 
 
Methods 
This article uses data from five focus groups conducted during the EURORDIS 
Membership Meeting at the European Conference on Rare Diseases 2014 in Berlin and 
the EURORDIS Summer School for Expert Patients 2014 in Barcelona. EURORDIS is 
an alliance of rare disease patient organisations with almost 700 member organisations 
across Europe. Sampling for the focus groups was purposive and targeted existing 
EURORDIS member organisations and most participants have personal or familial 
experiences of genetic technologies. 
 
Fifty-two people from sixteen different countries opted to join the focus groups – thirty-
two were women and twenty were men (table 1). Fifty of the participants were either 
people with a rare disease or the parent of a child/children with a rare disease and 
sometimes both. Two people were health professionals working in rare diseases. 
 
France 9 Denmark 2 
UK 9 Portugal 2 
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Germany 8 Slovakia 2 
Italy 4 Iceland 2 
Serbia 3 Belgium 1 
Netherlands 3 Czech Rep 1 
Greece 2 Ireland 1 
USA 2 Romania 1 
Table 1 – focus group participants by country of residence 
 
This was an exploratory study and therefore did not have a starting hypothesis. Instead, 
the participants raised issues which they considered of interest, rather than discussing 
specific topics decided by the researchers. This is a useful technique where so little is 
known about rare disease patients’ views on international data sharing and helps to 
identify and describe RD patients’ ideas and assumptions on this subject. The use of 
scenarios helps to stimulate the raising of self-identified issues. 
 
Focus groups were chosen for the ability to allow in-depth discussion among people with 
common interests, whether opinions are heterogeneous or homogeneous. In addition, it is 
thought that the format puts participants at ease which benefits the raising of sensitive or 
contentious issues 16,17 . 
 
The focus groups used two scenarios based on real life problems, which were the result 
of exploratory work in RD Connect involving project researchers, the Patient Advisory 
Council (PAC) and the Patient and Ethics Council (RD-PEC). The first scenario was 
based on the reuse of historical consents and issues around re-consenting patients in order 
to repurpose historical samples for a new study. The second scenario featured the 
Care.data scheme overseen by the National Health Service in England, which aimed to 
compile a national database of medical records from primary care organisations and 
hospitals, for use in research. The implementation of the Care.data scheme is delayed and 
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highly criticised for failure to communicate adequately with the public 
(http://www.bbc.co.uk/news/health-26259101). This example was used to stimulate 
discussion about what information people seek when considering participation in a large 
database for health research. The scenarios were designed to allow participants, rather 
than the researcher, to identify the specific topics for discussion and to talk about their 
own viewpoints and experiences. 
 
Scenarios are less restrictive than surveys and allow debate or conversations to be opened 
up between participants where they are given the opportunity to talk about their own 
behaviours, opinions and beliefs 18 19. They allow free participation, especially around 
sensitive or difficult topics, where focus group members can choose to be explicit about 
their own experiences or simply to draw on those, while at the same time keeping 
comments focussed on the scenario in hand 20. 
 
Focus groups were moderated, digitally recorded and lasted 60 to 90 minutes. Analysis 
was inductive but within a framework of previous exploratory work carried out in 
previous workshops with clinicians, scientists, bioethicists, patient advocates and 
industry representatives involved with RD-Connect, NeurOmics and EURenOmics. 
 
Results 
 Summary 
The members of the focus groups were positively disposed towards participating in 
research and allowing their own data and biosamples, as well as those of any affected 
children, to be shared internationally. All the participants understood the incentive for 
7 
 
RD in sharing data and samples, in fact there were several pleas for research systems to 
be standardised across the EU in order to make data sharing easier. 
 
Before participants would be willing to participate in a centralised database, they would 
seek information about governance and management, especially around who has access 
to data in the platform. In addition participants were interested in how patient advocacy 
organisations would be involved in the ongoing supervision of a global platform for RD. 
 
Individuals’ levels of trust and attitudes to risk differed and while a large majority of the 
participants were concerned about threats to privacy and autonomy, the scale and scope 
of these concerns varied between individuals. Individuals’ approaches were often 
bounded culturally and this included: politically and socially mediated practices and 
norms in the country in which they lived; the characteristics of the rare disease that they 
and/or their child had; and individual experiences with research. 
 
All these influences made participants reflect on data sharing and linking, including the 
benefits and risks, in slightly different contexts. They quoted recent examples of 
perceived misuse of technology or leaking of data as background to ongoing concerns 
about the privacy of their data in any system, such as revelations by former CIA 
employee Edward Snowden that USA intelligence services routinely conducted illegal 
surveillance of individuals’ data (http://www.theguardian.com/us-news/the-nsa-files). 
 
The participants understand that futures can be uncertain and the nature of that 
uncertainty cannot be predicted and in light of this they look for safeguards and stability 
within research systems which will go some way towards ameliorating risks. The 
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discussion here highlights four themes which emerged from the data and illustrate factors 
that are important to RD patients and families when they are considering participation in 
research. 
 
Consent for historical samples and data 
Using the scenario example of a clinician-researcher assessing whether or not she should 
re-contact and re-consent participants to allow the re-use of historic samples and data, 
most participants felt very strongly that participants should be re-contacted if the specific 
usage was not covered in the original consent. The introduction of certain conditions, 
such as the anonymisation of samples or the disorder being ultra-rare did not affect their 
viewpoint on this. 
 
A variety of reasons were invoked including genetic exceptionalism, which is the notion 
that genetic data has particular importance and should be treated differently to other 
health data 21 and the possibility that the new use might not fit with the participant’s 
values, for example using embryonic stem cells. This is the notion of “you should at least 
ask”, and it can be discerned that the decision to participate in a new study should be the 
patient’s/parent’s alone and that this decision should be reached without the invocation of 
persuasive elements, such as the study being for an ultra-rare condition. 
 
To most participants the possibility of the researcher applying to a research ethics 
committee to proceed without re-consenting individuals, was seen as a threat to both 
individual and group autonomy and to trust. In addition there is the notion here of group 
solidarity where the participant feels beholden to the group to behave in a manner 
morally acceptable to other parents. Other participants evoked equality of treatment 
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across all samples in the study, ‘The, um, samples that you’re taking at the moment, 
presumably, she would have to go through having everybody sign an informed consent 
form … She would have to go through that process with the new ones. Right? …  So you 
can’t have a two tier situation with one group giving open consent and the other group 
being assumed not to have consent’. 
 
Several participants see informed consent as a contract where both sides promise to 
honour the agreement, and that to proceed with a study without re-consenting participants 
is to modify the terms of this agreement without the knowledge of the other party. 
 
While all the participants recognised the benefit of making the most of rare samples that 
can be difficult to re-collect, only a minority thought that samples and/or data should be 
used without re-consent. For these participants the use of anonymisation and ethical 
review was sufficient. Justification included that there was no or little risk, that wastage 
of precious samples and data should be avoided, and the resources used for re-consent 
represented an opportunity cost for some other aspect of the research. In addition, the fact 
that there are temporal aspects to rare diseases which are progressive and/or life-limiting, 
where the move towards a cure is imperative and is a critical factor for families, is seen 
by a minority of participants to be a driver to making use of as many samples and data as 
possible. 
‘I’m probably gonna have complications of this disease exactly the way my grandmother, 
my great-grandmother did and my mother will, but [my daughter] is two and a half, I 
hope that in the next fifteen years something comes up before it starts like big time… so 
the question is, with so little time, personally, I’d say, let’s use whatever is there. 
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Consent – re-consent and children 
There was debate within the focus groups about whether children or their families should 
be contacted to seek re-consent when a child comes of age. There were broadly two sets 
of views, the first was that the original consent is legitimate and should stand without re-
contact and the second, that it was unacceptable to reuse a sample for someone who was 
now an adult and had not consented for themselves. Arguments put forward for the first 
view included opposition to project resources being spent on re-contact and re-consent 
where there was no requirement to do so as well as the consideration that re-contact 
could be upsetting for a family if the child had died. Participants in favour of re-consent 
thought that re-contact was desirable in any circumstances – that the child-now-adult’s 
autonomy should be respected by giving them an opportunity to make their own decision 
about participation. 
 
Counter to the previous argument, this group thought that ongoing communication with 
the child-now-adult and the family would be beneficial and would show that research 
into the condition was ongoing and the child’s sample still had utility and that re-contact 
had the role of respecting the family’s autonomy. 
‘I think it could be an opportunity to let them know that we are still fighting to find drugs 
or something better for new patients who have the same disease as their daughter or son 
and I think … let people know that we are still looking for a solution and we are also 
looking for fundraising, for everything like this and it’s an opportunity’. 
 
Data sharing and access to data 
Use of a scenario based on the attempted implementation of the Care.data scheme in 
England prompted discussion around the conditions under which data sharing should 
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take place. Most of the focus group attendees would not give permission for their records 
to be used under the broad and indeterminate circumstances illustrated by the scenario 
and would be unhappy with an opt-out system. In order to join or give consent for their 
data to be included in a ‘broad use’ database they would seek specific information on 
curatorship, governance and details about access and security. Participants were in favour 
of systems run by public or not-for-profit organisations such as universities, hospitals and 
clinics. 
 
Most participants would like to limit access to their records to people working in 
healthcare and health research. All participants were against the data being accessed by 
private companies. Even when prompted that pharmaceutical companies need access to 
patient data and records for drug development and clinical trials, participants were of the 
view that this should only be allowed in partnership and via not-for-profit health 
organisations. 
‘I’m very worried about independence, about studies in general, I’m very worried about 
pharmaceutical companies coming in… so I wouldn’t like this to become, I’m selling you 
a list of people with this, I don’t know, I just, I feel uncomfortable. It would take too long 
to explain all my point of views but that makes me feel very, very uncomfortable, first and 
because I don’t feel protected’. 
 
Participants were also concerned about the stability of private companies and this was 
illustrated by an Icelandic participant who had recently been approached by deCODE to 
provide a sample for genomic analysis to add to their database. She prefaced her story by 
stating that deCODE’s founder was severely affected by the Icelandic economic crash of 
2008. In fact deCODE filed for bankruptcy at this time and were subsequently acquired by 
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the American company Amgen and in turn by the Chinese company WuXi Pharma Tech 
in 2015. There is a tension between what participants see as the private nature of people’s 
health records and DNA and the international, market-driven approach of a company. 
 
Management, governance and security 
Participants’ high levels of criticism about what they saw as vague assurances and a lack 
of detail given in the Care.data example emphasises the need for detailed, relevant 
information and also that different people require information about different areas of 
governance and management. Some focus group participants were more interested in 
knowing that researcher’s activity on the system was tracked whereas others would seek 
technical detail on types of security used for the whole system. One participant likened 
the situation to a bank, where you deposit your money on the grounds that there are 
agreed levels of protection for your funds. 
‘I’m just trying to say there is this framework, you know we say that there is a 
governance system in place which will protect the patient and we can look at them like 
we do the financial institutions and we’re quite happy with how they exist, well they’re 
quite well developed. There’s a frameworks around this and we want some assurance’. 
 
Participants seek protection from: their data being used for a purpose for which they did 
not consent; the possibility of discrimination through their data being made available to 
an employer or government department; and from other uncertainties. There was a 
particular concern about the possibility of insurance companies gaining access to data 
and using this to make decisions with regard to the provision of health or other types of 
insurance. 
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There was an acute recognition, among those taking part in the focus groups, of the 
vulnerability inherent in being identified as having a rare disease and possibility that 
open knowledge of this could lead to discrimination in a number of quarters such as 
employment or the provision of financial services. 
 
Inclusion of patient organisations in governance 
One of the means of meeting participants’ expectations of protection is to ensure that 
patient organisations are represented in ongoing governance of a global database. Focus 
group attendees were of the view that the experiential knowledge of patient groups could 
contribute to good governance of a global platform.  
 
‘Well I am just coming back on this capacity development for patient organisation – I 
think it’s a very key, not just with this project but with many other projects – if we want 
to control, to have a good governance of this project, we need to have citizen and patient 
on board and we need to raise their capacity’. 
 
Some participant’s ideas of collaboration went further than this as they thought patient 
organisations had a duty to encourage clinicians and researchers to collaborate in 
populating a global platform for research. 
 
‘I think this is our task, to put them together and now I think, there are changes in the 
mind of the doctors … there is a lot of work to do, but we only can do it together with 
you, so it’s our task to tell them that they are open-minded, and to convince other doctors 
to be open-minded, and I think there is really the change now’. 
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Risk/benefit 
There is a strong notion among the focus groups discussion of personal choice in that 
participants take decisions which they deem correct for themselves or their child and 
which they feel comfortable with. They recognise that others, even in the same 
circumstances, might feel and therefore act differently. One participant gave the analogy 
that some people willingly use credit cards online while others avoid this and that 
participants undertake their own risk/benefit audit in each circumstance. 
 
Participants who value the benefits of data and sample sharing as outweighing any 
potential risks often do so on an individual basis and are not prepared to take a position 
on behalf of the patient organisation they represent, but rather highlight the importance of 
each patient making such decisions for themselves. 
 
Risk versus benefit decisions can also be informed by the characteristics of the disease as 
illuminated in a lively debate during the focus groups between two mothers of children 
with RD. The mother of a child with a progressive, life-limiting disorder who was 
prepared to be relatively permissive about giving consent and sharing data on the grounds 
that, “our biggest vulnerability is the fact that we don’t have a cure. We don’t have… We 
don’t have time, that’s the way I see it”. 
 
In direct contrast a mother of a child with an inherited intellectual disability was 
concerned about discrimination and used the example of past cultural norms of societal 
exclusion of people with intellectual disability as a reason to proceed with caution in 
sharing data which identifies such difference “…but what about, inherited intellectual 
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disabilities, which years ago, like people were institutionalised…so it’s a just different way 
of thinking for intellectual disability”. 
 
Participants cited many other risks, such as being re-identified by a researcher compiling 
records from several different sources and unattributed paternity. Many of them though 
talked about multiple aspects of daily life – employment, insurance (including health 
insurance), financial services and healthcare provision – where they feared being 
discriminated against if access to data was not strictly controlled. 
 
Discussion 
Opinions on consent in these focus groups indicate that participants are keen to retain 
autonomy, for themselves and for the group they might represent, by being given the 
opportunity to consent or re-consent when research purposes change. Some see consent 
as a contract which should be honoured by both sides. Consent for medical research is a 
type of contract and has legal status and conditions which are legally enforceable 22. It 
would appear though that members of the focus groups are not thinking solely of a 
functional, legal role for consent and have moved beyond the gift relationship 23 to seeing 
consent as a social agreement where they reject that decisions should be taken by a 
researcher or ethics board 24 25. 
This is especially important given current debates around broad consent versus dynamic 
consent 26. Many rare disease patients and their families have prolonged contact, with 
research teams and there are strong notions in the findings of a duty to participate in 
order to aid research progress. It seems that participants expect clinicians and researchers 
to have concordant duties, including consulting with the patient/family if there is a 
possibility that new research moves beyond the bounds of the original informed consent. 
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In Gottweis et al’s words, ‘people need to feel that they are part of something larger and 
that their donation feeds into a mutual, respectful relationship’ 27. 
This mutuality extends to the idea of renewing contact when a child is potentially coming 
of age. While there is no current legal requirement for children to be re-consented on 
reaching adulthood, the general consensus in the ethics literature 28 is that children should 
be re-consented when they reach the age of majority or provided with information and 
the opportunity to opt out. In a recent study among young adult cancer survivors, whose 
tissue and data was lodged in a biobank when they were children, 70% were unaware of 
their participation yet 100% agreed their tissue could continue to be used, illustrating the 
importance of re-contact for their individual autonomy as adults and for mutuality of 
decision-making 29. 
Focus group participants saw re-contact as crucial in all circumstances and re-contact 
was viewed as a positive interaction. These ongoing, long term interactions can build 
trusting relationships between researchers, clinicians and patients which can ultimately 
have a positive impact on participation 14,30. 
Concerns about data sharing and access and around private companies is in common with 
other studies30-33. In many cases participants were concerned about the risk of stigma and 
discrimination against themselves or their children which they perceive could have a 
negative impact on access to healthcare and other opportunities in life. These are 
Goffman’s discredited citizens, not fully accepted by society 34, where “families have the 
capacity to construct a ‘protective capsule’ for their stigmatized child’s identify 
formation, through the control of information to the child and to the outside community” 
35. 
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The pernicious effects of discrimination are real and recent experiences for many people 
with rare diseases and their families 36,37 and while genetic discrimination is banned in 
most of the countries that our participants are from, it is not always present in legislation 
or treated in the same manner throughout the EU, USA and Canada 38. 
It is therefore important for rare disease patients and families to mitigate, as far as 
possible, against uncertainties which might lead to their data “getting into the wrong 
hands”. Participants have high levels of trust in public institutions 39 and expect such 
organisations to protect against the possibility of participation in a global database 
leading to disadvantage, especially given concerns about possible, unknown changes in 
political landscape, regulation or legislation.  
 
Given that most of the participants in this study were involved in executive or 
management activities in a rare disease organisation and many were operating 
proficiently with English as a second language, they are not likely to be from a wide 
variety of social backgrounds. It was vital for this research that participants understood 
how RD research infrastructures operate and it was therefore necessary to focus on these 
‘expert patients’. It is of course possible that RD patients and families from different 
socio-economic backgrounds, or with a worldview that does not include a role as a RD 
advocate, would have different opinions from the focus group participants. 
That said, they represent a significant number of rare disease representatives for a 
qualitative study and are in a position to provide important insight into issues around 
genomic technologies and international data sharing which are likely to affect all 
research in the future, and not just the field of rare disease. 
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Conclusion 
In this analysis we have established that rare disease patients and parents see their 
dealings with researchers as motivated by common interests and participants are keen to 
make their samples and data available to researchers as long as this action is treated with 
respect and reciprocity. 
As their data and samples are shared and used by researchers around the world, 
participants could perceive that the locus of influence has shifted and their control over 
information about their and their family’s health is diminished. Hence the strongly 
expressed desire to protect their and their children’s autonomy, and to protect against 
lapses in privacy and the potential for subsequent discrimination. 
One of the means of doing this is to ensure that patient organisations are represented in 
ongoing governance of a global platform like RD-Connect, as part of ensuring that 
participants feel they have an equivalent level of protection and control in these global 
interactions as they do in their local relationships with researchers. 
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